Vistagen and affamed complete key regulatory submissions for palisade global phase 3 clinical trial for ph94b

South san francisco, calif. & shanghai--(business wire)--vistagen therapeutics, inc. (nasdaq: vtgn) (vistagen) and affamed therapeutics (affamed) today announced they have completed regulatory preparations to initiate palisade global, a phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of vistagen's ph94b (referred to by affamed as am005) for the acute treatment of anxiety in adults with social anxiety disorder (sad), in the u.s. and china. the primary purpose of palisad
VTGN Ratings Summary
VTGN Quant Ranking